# Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions

> **NCT05552495** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 31 (actual)

## Conditions studied

- Hypertension and Dyslipidemia

## Interventions

- **DRUG:** CKD-386(4) F1
- **DRUG:** CKD-386(4) F2
- **DRUG:** D013, D326, D337

## Key facts

- **NCT ID:** NCT05552495
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-23
- **Primary completion:** 2022-11-27
- **Final completion:** 2022-12-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2023-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05552495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05552495, "Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05552495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*